技術指標
指標
數值
方向
MACD(12,26,9)
-0.460
賣出
RSI(14)
39.248
中性
STOCH(KDJ)(9,3,3)
7.871
超賣
ATR(14)
0.863
低波動
CCI(14)
-128.163
賣出
Williams %R
95.563
超賣
TRIX(12,20)
-0.110
賣出
StochRSI(14)
0.000
超賣
搜尋
EyePoint Pharmaceuticals Inc
EYPT添加自選
12.190USD
-0.280-2.25%
收盤 07-24 16:00（美東）報價延遲15分鐘
1.01B總市值
虧損本益比TTM
關鍵數據
12.450今開
12.498最高
1.47M成交量
虧損本益比TTM
虧損本益比動
--股利TTM
1.77%換手率
12.470昨收
12.060最低
13.63M成交額
虧損本益比靜
3.30市淨率
0.00%股息率 TTM
-83.47%ROA
19.11052週最高
1.13量比
-130.87M淨利潤
82.83M總股本
-3.5053每股盈餘TTM
1.74Beta
-102.71%ROE
6.85052週最低
3.51%振幅
24.14%毛利率
1.01B總市值
-2.07回報/風險
4.20%風險率
TradingKey EyePoint Pharmaceuticals Inc股票評分
單位: USD 更新時間: 2026-07-24操作建議
EyePoint Pharmaceuticals Inc當前公司基本面數據相對健康，增長潛力較大。當前估值合理，在藥品行業排名69/155位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為40.50。中期看，股價處於平穩狀態。近一個月，市場表現較差，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
EyePoint Pharmaceuticals Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
EyePoint Pharmaceuticals Inc亮點
亮點風險
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
業績增長期
公司處於發展階段，最新年度總收入31.37M美元
利潤高增長
公司淨利潤處於行業前列，最新年度總收入31.37M美元
估值高估
公司最新PE估值-3.48，處於3年歷史高位
機構減倉
最新機構持股88.53M股，環比減少3.02%
活躍度增加
近期活躍度增加，過去20天平均換手率0.53
分析師目標
基於
14
分析師
買入
評級
41.077
目標均價
+229.41%
漲幅空間
EyePoint Pharmaceuticals Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
收益預測
分析師評級
基於
14
分析師
買入
評級
41.077
目標均價
+229.41%
漲幅空間
強力買入
買入
持有
賣出
強力賣出
同行比較
160
總數
6
中位數
9
平均值
公司名稱
評級分佈
分析師數
EyePoint Pharmaceuticals Inc
EYPT
14
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
艾伯維
ABBV
34
輝瑞
PFE
32
1
2
3
...
32
技術指標
移動平均線
指標
數值
方向
MA5
12.606
賣出
MA10
13.123
賣出
MA20
13.625
賣出
MA50
13.158
賣出
MA100
13.578
賣出
MA200
14.126
賣出
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
EyePoint Pharmaceuticals Inc簡介
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
公司代碼EYPT
公司EyePoint Pharmaceuticals Inc
CEODuker (Jay S)
網址https://eyepointpharma.com/
公司股東
相關品種
+0.88%
+1.60%
+0.43%
+0.90%
+0.46%
-0.72%
+1.22%
+1.25%
-1.18%
-0.12%
+0.94%
+0.90%
+1.20%
-0.02%
+2.04%
0.00%
+0.63%
-0.69%
+2.59%
+0.89%熱門品種
51900.000
+176.000 (+0.34%)
28150.400
-427.600 (-1.50%)
7408.100
-11.800 (-0.16%)
14948.000
-153.000 (-1.01%)
64219.000
-1152.000 (-1.76%)
6264.500
+48.800 (+0.79%)
90.043
-2.069 (-2.25%)
333.020
+11.360 (+3.53%)
206.840
-1.920 (-0.92%)
4052.350
+2.980 (+0.07%)
常見問題
EyePoint Pharmaceuticals Inc(EYPT)的當前股價是多少？
EyePoint Pharmaceuticals Inc(EYPT)的當前股價是 12.19。
EyePoint Pharmaceuticals Inc 的股票代碼是什麼？
EyePoint Pharmaceuticals Inc的股票代碼是EYPT。
EyePoint Pharmaceuticals Inc股票的52週最高點是多少？
EyePoint Pharmaceuticals Inc股票的52週最高點是19.11。
EyePoint Pharmaceuticals Inc股票的52週最低點是多少？
EyePoint Pharmaceuticals Inc股票的52週最低點是6.85。
EyePoint Pharmaceuticals Inc的市值是多少？
EyePoint Pharmaceuticals Inc的市值是1.02B。
現在EyePoint Pharmaceuticals Inc(EYPT)的股票是買入、持有還是賣出？
根據分析師評級，EyePoint Pharmaceuticals Inc(EYPT)的總體評級為買入，目標價格為41.08。
EyePoint Pharmaceuticals Inc(EYPT)股票的每股收益（EPS TTM）是多少
EyePoint Pharmaceuticals Inc(EYPT)股票的每股收益（EPS TTM）是-3.17。